CMDh/EMA: Appendix 1 for Nitrosamines Revised

Recommendation
Wednesday, 19 November 2025 9 .00 - 16.30 h
In the current version of July 2024, the EMA/CMDh nitrosamine Q&A document "Questions and answers for marketing authorisation holders/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in human medicinal products" contains three appendices (Appendix 1-3). These documents are available on the EMA website under "Questions and answers".
Appendix 1 was compiled by the "Non-clincal Working Party (NcWP)" and the information provided for the Acceptable Intakes (AIs) is based on the "Carcinogenic Potency Categorization Approach (CPCA)". In February 2025, new substances were added to Appendix 1; the substances are listed in tabular form. The new entries are marked in red in the list of Acceptable Intakes (AIs) and are easily identifiable. The following substances are newly listed:
- 2-(N-nitrosomethylamino)-N-[6-(trifluoromethoxy)-1,3-benzothiazol-2-yl]acetamide
- N-nitroso-dalbavancin
- N-nitroso-dasatinib
- N-deshydroxyethyl-N-nitroso dasatinib
- N-nitroso-desmethyl-cabergoline
- N-nitroso-desmethyl-lercanidipine
- N-nitroso-desmethyl-lercanidipine impurity D
- N-nitroso-N-desmethyl-mianserin
- N-nitroso-norfloxacin
- N-nitroso-sarcosine
- N-nitroso-vancomycin
Appendices 2 and 3 as well as Appendix 1 and the Q&A document for nitrosamines can be viewed on the EMA website.
Related GMP News
03.07.2025USP: Chapter <1029> Good Documentation Guidelines and Data Integrity published for comment
25.06.2025IPEC: Revised Risk Assessment Guide for Pharmaceutical Excipients
18.06.2025USP: Comments possible on the Topic "Process Analytical Technology"
18.06.2025EMA/CMDh: Nitrosamine Q&A Document updated
11.06.2025APIC: Update of the Nitrosamine Guide
04.06.2025ICH: New Guideline for Stabilities